Please login to the form below

Not currently logged in
Email:
Password:

Merck enters Alzheimer's partnership

Merck has entered into a $289m research partnership with Alectos Therapeutics

Merck has entered into a research partnership with Alectos Therapeutics focused on compounds that modulate the enzyme -linked N-acetylglucosaminidase (O-GlcNAcase).

The deal, which is valued at $289m, gives Merck exclusive global rights to research, develop and commercialise compounds that modulate the target in return for an upfront payment, milestones, royalties, and research funding for Alectos' existing portfolio of compounds targeting Alzheimer's disease. 

The agreement calls for Alectos and Merck to partner on discovery and preclinical development, with Merck taking over full responsibility for clinical development. The companies may also develop products that modulate the enzyme as treatments for other neurological diseases.

Alectos was founded by researchers from Canada's Simon Frasier University.

11th August 2010

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Virtual MSL/Sales training programs and events
Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events...
6 trends shaping the future of personalized medicine
Senior Consultant Leah Carlisle explores the key trends discussed at the 16th annual Personalized Medicine Conference, providing expert analysis and key recommendations for biopharmaceutical innovators....
Omnichannel strategies to revolutionize the healthcare professional experience
Fishawack Health’s omnichannel experts unite to reveal how medical and commercial teams can build more meaningful experiences for healthcare professionals. They discuss the opportunities of omnichannel and explore how the...